Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor - PubMed (original) (raw)
Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor
Jill M Kramer et al. J Immunol. 2007.
Abstract
IL-17 is the hallmark cytokine of the newly described "Th17" lymphocyte population. The composition, subunit dynamics, and ligand contacts of the IL-17 receptor are poorly defined. We previously demonstrated that the IL-17RA subunit oligomerizes in the membrane without a ligand. In this study, computational modeling identified two fibronectin-III-like (FN) domains in IL-17RA connected by a nonstructured linker, which we predicted to mediate homotypic interactions. In yeast two-hybrid, the membrane-proximal FN domain (FN2), but not the membrane-distal domain (FN1), formed homomeric interactions. The ability of FN2 to drive ligand-independent multimerization was verified by coimmunoprecipitation and fluorescence resonance energy transfer microscopy. Thus, FN2 constitutes a "pre-ligand assembly domain" (PLAD). Further studies indicated that the FN2 linker domain contains the IL-17 binding site, which was never mapped. However, the FN1 domain is also required for high affinity interactions with IL-17. Therefore, although the PLAD is located entirely within FN2, effective ligand binding also involves contributions from the linker and FN1.
Conflict of interest statement
Disclosures
The authors have no financial conflict of interest.
Figures
FIGURE 1
The FN2 domain of IL-17RA mediates ligand-independent assembly. A, Predicted structure of IL-17RA FN domains. PHYRE predicted two FN domains within the mouse IL-17RA ECD. Yellow, _β_-Sheets; red, _α_-helices; green, unstructured loops; blue, turns. Sequences of each domain are shown. B, Schematic diagram of IL-17RA FRET and Y2H constructs. SEFIR is a major signaling domain in IL-17RA (22). AD, Activation domain; BD, binding domain. C, FN2linker drives ligand-independent association in cells. HEK293 cells expressing the indicated combinations of IL-17RA constructs fused to CFP or YFP were assayed for N-FRET in the absence (open bars) or presence of IL-17 (filled bars) or IL-17F (gray bar) for 10 min. Significance was assessed by t test, p < 0.05; n.s., not significant. D, Representative images of IL-17RAΔ/CFP plus IL-17RAΔFN2linker/YFP. CFP, YFP, and FRET emissions are shown. Unstim., Unstimulated. E, IL-17RA can co-IP with IL-17RAΔFN2linker. HEK293 cells expressing IL-17RAΔFN2linker/YFP were transiently transfected with IL-17RA.HA. Cells were lysed and immunoprecipitated (IP) with anti-HA or M177 anti-IL-17RA Abs and immunoblotted with Abs to GFP (which cross-react with YFP) or HA. Note that we always observe slight cross-reactivity of anti-HA Abs with YFP and CFP for unknown reasons. W, Western blot.
FIGURE 2
Requirements for IL-17 signaling and binding. A, The FN1 domain is dispensable but the linker is required for IL-17-dependent signaling. IL-17RA−/−fibroblasts were transfected in triplicate with the indicated IL-17RA constructs (with FL cytoplasmic tails) and 24p3-Luc (18). Cells were stimulated with IL-17 (200 ng/ml) and/or TNF-α (2 ng/ml). After 6 h, luciferase activity was determined and normalized to Renilla luciferase. B and C, IL-17RA-neutralizing Abs bind the FN2linker domain. B, HEK293 cells stably transfected with IL-17RΔ/CFP (top) or transiently transfected with IL-17RAΔFN2linker/CFP (bottom) were incubated with a non-neutralizing (clone M177) or neutralizing Ab (clone M750) to murine IL-17RA. Filled histograms are isotype controls. C, Whole cell lysates from HEK293 cells stably expressing IL-17RAΔ/CFP or IL-17RAΔFN2linker/YFP were immunoprecipitated (IP) with M750 or M177 as indicated and blotted with anti-GFP Abs. D and E, FN2linker has a reduced affinity for IL-17. HEK293 cells stably expressing IL-17RAΔ/CFP or IL-17RAΔFN2linker/YFP were stained with various concentrations of IL17.Fc after blocking endogenous human IL-17RA (D) or with M750 (E). F, The linker is required but not sufficient for IL-17 binding. HEK293 cells transiently transfected with IL-17RAΔ/YFP, IL-17RAΔFN1linker/YFP, or IL-17RAΔFN2/YFP were stained with IL17.Fc and gated on YFP-positive cells.
FIGURE 3
Model of IL-17RA subunit dynamics. Data suggest that the cytoplasmic tails of IL-17RA are held in proximity before ligand binding (A), but separate upon binding IL-17 (B). Based on FRET, at least one FN1 domain is sufficient to mediate ligand-induced subunit reconfiguration (C). However, in the absence of both FN1 domains the cytoplasmic tails show increased association (D). IL-17 requires the FN2 and linker regions to bind the receptor but may also contact FN1 (B_–_D).
Similar articles
- Structural basis of receptor sharing by interleukin 17 cytokines.
Ely LK, Fischer S, Garcia KC. Ely LK, et al. Nat Immunol. 2009 Dec;10(12):1245-51. doi: 10.1038/ni.1813. Epub 2009 Oct 18. Nat Immunol. 2009. PMID: 19838198 Free PMC article. - Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signaling.
Zhang B, Liu C, Qian W, Han Y, Li X, Deng J. Zhang B, et al. Acta Crystallogr D Biol Crystallogr. 2014 May;70(Pt 5):1476-83. doi: 10.1107/S1399004714005227. Epub 2014 Apr 30. Acta Crystallogr D Biol Crystallogr. 2014. PMID: 24816115 Free PMC article. - ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.
Hlavničková M, Kuchař M, Osička R, Vaňková L, Petroková H, Malý M, Černý J, Arenberger P, Malý P. Hlavničková M, et al. Int J Mol Sci. 2018 Oct 9;19(10):3089. doi: 10.3390/ijms19103089. Int J Mol Sci. 2018. PMID: 30304852 Free PMC article. - An Overview of Interleukin-17A and Interleukin-17 Receptor A Structure, Interaction and Signaling.
Krstic J, Obradovic H, Kukolj T, Mojsilovic S, Okic-Dordevic I, Bugarski D, Santibanez JF. Krstic J, et al. Protein Pept Lett. 2015;22(7):570-8. doi: 10.2174/0929866522666150520145554. Protein Pept Lett. 2015. PMID: 25990083 Review. - Th17 cells and mucosal host defense.
Aujla SJ, Dubin PJ, Kolls JK. Aujla SJ, et al. Semin Immunol. 2007 Dec;19(6):377-82. doi: 10.1016/j.smim.2007.10.009. Epub 2007 Nov 28. Semin Immunol. 2007. PMID: 18054248 Free PMC article. Review.
Cited by
- IL-17A and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection.
Tsai HC, Velichko S, Hung LY, Wu R. Tsai HC, et al. Clin Dev Immunol. 2013;2013:267971. doi: 10.1155/2013/267971. Epub 2013 Jul 17. Clin Dev Immunol. 2013. PMID: 23956759 Free PMC article. Review. - Structural basis of receptor sharing by interleukin 17 cytokines.
Ely LK, Fischer S, Garcia KC. Ely LK, et al. Nat Immunol. 2009 Dec;10(12):1245-51. doi: 10.1038/ni.1813. Epub 2009 Oct 18. Nat Immunol. 2009. PMID: 19838198 Free PMC article. - IL-17RC: a partner in IL-17 signaling and beyond.
Ho AW, Gaffen SL. Ho AW, et al. Semin Immunopathol. 2010 Mar;32(1):33-42. doi: 10.1007/s00281-009-0185-0. Epub 2009 Dec 13. Semin Immunopathol. 2010. PMID: 20012905 Free PMC article. Review. - Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites.
Saenz SA, Taylor BC, Artis D. Saenz SA, et al. Immunol Rev. 2008 Dec;226:172-90. doi: 10.1111/j.1600-065X.2008.00713.x. Immunol Rev. 2008. PMID: 19161424 Free PMC article. Review. - Role of IL-17 in psoriasis and psoriatic arthritis.
Raychaudhuri SP. Raychaudhuri SP. Clin Rev Allergy Immunol. 2013 Apr;44(2):183-93. doi: 10.1007/s12016-012-8307-1. Clin Rev Allergy Immunol. 2013. PMID: 22362575 Review.
References
- Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852. - PubMed
- Cua DJ, Kastelein RA. TGF-β, a “double agent” in the immune pathology war. Nat Immunol. 2006;7:557–559. - PubMed
- Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18:670–675. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- DE07034/DE/NIDCR NIH HHS/United States
- T32 DE007034/DE/NIDCR NIH HHS/United States
- DE14831/DE/NIDCR NIH HHS/United States
- R21 AI049329/AI/NIAID NIH HHS/United States
- F30 DE014831-04/DE/NIDCR NIH HHS/United States
- F30 DE014831/DE/NIDCR NIH HHS/United States
- R01 AI049329/AI/NIAID NIH HHS/United States
- AR05048/AR/NIAMS NIH HHS/United States
- AI49329/AI/NIAID NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous